MTOR and Parkinson disease: mTOR inhibitors, such as rapamycin, but not ribosomal protein S6 kinase inhibitors, have been indicated in in vivo models as combination therapy with standard antiparkinsonian agents to alleviate motor symptoms and cognitive symptoms of PD [223, 224].